Aptorum Group Ltd - רווח נקי למניה אחת בשנים עשר החודשים האחרונים APM
The Aptorum Group Limited (APM) ecosystem develops treatments for infections and orphan pathologies utilizing the Smart-ACT platform. Development efficiency is sustained by outsourcing tests to external contractors under strict cost audits. The annual shift in EPS TTM visualizes the result of this synergy, with the metric holding at -1985.00. Business scalability is ensured by selling molecule rights to industry behemoths, thereby eliminating capital expenditures for manufacturing plants.
פילוחי מדדים פיננסיים ומדדי שוק עבור Aptorum (APM)
Aptorum Group Limited simplifies the balance between operating expenses and return on equity through the outsourcing of clinical trials and a lean workforce. By analyzing the EPS growth rate over the last 12 months YoY, an investor can track the net profit per share, allowing for an assessment of the business model's resilience and the risk of multiple compression during a shift in the market cycle.
